Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments
Histologic confirmation of the original primary tumor is required
Histologic or cytologic confirmation of the recurrent/progressive disease is desired
Patients must have had at least one but no more than two prior chemotherapeutic regimens for management of endometrial carcinoma
Disease that is measurable per RECIST v1.1
No active infection requiring antibiotics
Any hormonal therapy directed at the malignant tumor must be discontinued at least 2 weeks prior to first study treatment
Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatment
Adequate hematologic and end organ function
You may not be if
Type I diabetes or Type II diabetes requiring insulin
Prior use of mTOR/PI3K inhibitor
Current dyspnea at rest or any requirement for supplemental oxygen therapy to perform activities of daily living
Previous diagnosis of pulmonary fibrosis of any cause
History of myocardial infarction or unstable angina within 6 months prior to first study treatment
Congestive heart failure
History of malabsorption syndrome or other condition that would interfere with enteral absorption
Clinically significant history of liver disease, including cirrhosis and current alcohol abuse
Presence of positive test results for hepatitis B or hepatitis C
Known HIV infection
Active autoimmune disease that is not controlled by nonsteroidal anti inflammatory drugs
Need for current chronic corticosteroid therapy
Pregnancy, lactation, or breastfeeding
Current severe, uncontrolled systemic disease
Major surgical procedure or significant traumatic injury within 28 days prior to Day 1 or anticipation of the need for major surgery during the course of study treatment
Uncontrolled hypercalcemia
Leptomeningeal disease as a manifestation of cancer
Known untreated or active brain metastases
Grade \>=2 hypercholesterolemia or hypertriglyceridemia
Clareo Health | A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
